IPO

Recursion Pharmaceuticals Inc. uses machine learning to hunt for new therapies. The company raised $436 million in an upsized initial public offering priced at the top of a marketed range. Last week , the Salt Lake City-based company sold about 24 million shares for $18 each. Recursion is among a crop of new startups called … Read more

Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the human proteome, and Arya Sciences Acquisition Corp III, a special purpose acquisition company or SPAC, sponsored by Perceptive Advisors, announced in February a definitive business combination agreement. The combined company is expected to receive proceeds of approximately $350 million at the closing … Read more

Sensei Biotherapeutics, Inc., a Phase 2 biotech company based in Rockville, MD, is a developing bacteriophage-based platform for cancer therapies. In the first week of February, the company raised $133 million by offering 7 million shares at $19, above the range of $16 to $18. Sensei’s ImmunoPhage platform uses bacteriophage to induce an innate and … Read more

NexImmune, Inc, based in Gaithersburg, MD, is a clinical-stage biotechnology company developing immunotherapies that employ the body’s own T cells to generate a specific, potent and durable immune response that mimics natural biology. The company’s nanotechnology platform was originally developed at Johns Hopkins University. The backbone of the company’s approach is its Artificial Immune Modulation, … Read more

A special purpose acquisition company (SPAC) is a type of “blank-check” company that raises capital through initial public offerings (IPOs) with the intention to use the proceeds to acquire other companies at a later time. Unlike traditional IPOs, SPACs do not have commercial operations at the time of the IPO, explaining why they are referred … Read more

Decipher Biosciences, a commercial-stage precision urology oncology company, has filed with the U.S. Securities and Exchange Commission (SEC) to raise up to $100 million in an IPO. Decipher’s prostate cancer genomic testing products surface information about the underlying biology of a patient’s tumor. The company applies machine learning algorithms to help physicians improve therapy selection … Read more

Cullinan Oncology, LLC, a Cambridge, MA-based company, plans to raise about $150 million by offering 8.3 million shares at a price range of $17 to $19. At the midpoint of this range, Cullinan’s market value would be $750 million, fully diluted. The company is focused on developing a diversified pipeline of targeted oncology and immuno-oncology … Read more

Abcellera is an early-stage anti-body based drug discovery company that employs an AI powered platform to develop various therapies. The company has raised approximately $483 million in a recent IPO that was well received by the marketplace. According to Abcellera, the new frontier of technology lies at the interface of computation, engineering and biology – … Read more

Codiak Biosciences is developing exosome-based therapeutics to treat diseases. Exosomes are naturally-occurring extracellular vesicles that carry proteins, genetic material, and other substances in and out of cells. Exosomes are like tiny bubbles that were originally believed to be a cellular waste product. Instead, exosomes can also be engineered for selective targeting of particular cells (ie. … Read more

SQZ Biotech IPO’d in November with a $350 million+/- market cap on the basis of a new technology called Cell Squeeze®. What we can observe about this company in the present is limited to a very short history and is mostly anecdotal and risky. The company and the science is a good example of how … Read more